Shanghai Henlius Biotech Inc. (HKG: 2696), a prominent biopharmaceutical company based in China, has announced an expansion of its licensing agreement with Sermonix Pharmaceuticals Inc., to include additional territories in Asia for the development and commercialization of HLX78 (oral lasofoxifene). This supplementary agreement facilitates a co-development partnership between Henlius and Sermonix for the expedited advancement of HLX78 in Japan. The original licensing deal, focused on the China market, was established in January 2024.
HLX78 (oral lasofoxifene) is a clinical-stage investigational therapy that targets endocrine pathways, particularly as an ESR1 antagonist in breast tissue, showing significant promise in the presence of ESR1 mutations. In May 2024, the drug was granted permission to participate in the global registrational ELAINE-3 trial in China. The ELAINE-3 trial (NCT05696626) is the third in a series evaluating the efficacy of oral lasofoxifene in combination with a CDK4/6 inhibitor. The trial is set to enroll 400 pre- and post-menopausal patients with locally advanced or metastatic ER+/HER2- breast cancer who possess an ESR1 mutation.- Flcube.com
